Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002387402 | SCV002690954 | uncertain significance | Cardiovascular phenotype | 2021-10-05 | criteria provided, single submitter | clinical testing | The p.I330V variant (also known as c.988A>G), located in coding exon 8 of the RAF1 gene, results from an A to G substitution at nucleotide position 988. The isoleucine at codon 330 is replaced by valine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV003655379 | SCV004554118 | uncertain significance | RASopathy | 2024-08-13 | criteria provided, single submitter | clinical testing | This sequence change replaces isoleucine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 330 of the RAF1 protein (p.Ile330Val). This variant is present in population databases (rs756942422, gnomAD 0.006%). This variant has not been reported in the literature in individuals affected with RAF1-related conditions. ClinVar contains an entry for this variant (Variation ID: 1768494). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |